A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis.
Peter C TaylorDésirée Mfm van der HeijdeRobert B M LandeweShannon McCueSue ChengAnnelies BoonenPublished in: The Journal of rheumatology (2021)
No clinical benefit was observed with apremilast treatment in patients with active AS. The safety and tolerability of apremilast were consistent with its known profile.